Redhill Biopharma
RDHL
#11160
Rank
HK$19.57 M
Marketcap
HK$2.20
Share price
-13.08%
Change (1 day)
-72.79%
Change (1 year)

Earnings for Redhill Biopharma (RDHL)

Earnings in 2022: -HK$0.57 Billion

According to Redhill Biopharma's latest financial reports the company's current earnings are HK$35.74 Million. In 2022 the company made an earning of -HK$0.57 Billion, an increase over its 2021 earnings that were of -HK$0.77 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Redhill Biopharma from 2012 to 2022

Annual earnings

Year Earnings Change
2022-HK$0.57 Billion-26.68%
2021-HK$0.77 Billion28.32%
2020-HK$0.6 Billion80.06%
2019-HK$0.34 Billion8.97%
2018-HK$0.31 Billion-14.76%
2017-HK$0.36 Billion55.07%
2016-HK$0.24 Billion39.26%
2015-HK$0.17 Billion96.9%
2014-HK$83.97 Million0.78%
2013-HK$83.32 Million16.93%
2012-HK$71.25 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
HK$61.04 B 67,200.64%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$52.70 B 57,997.13%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$56.08 B 61,725.70%๐Ÿ‡ฌ๐Ÿ‡ง UK
Teva Pharmaceutical Industries
TEVA
HK$9.59 B 10,477.26%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Taro Pharmaceutical
TARO
HK$0.34 B 277.87%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel